A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results

Annals of Oncology

Volumn 8, Issue 7, 1997, Pages 649-654

  Bajetta, E ^a   Zilembo, N ^a   Barni, S ^a   Noberasco, C ^a   Martinetti, A ^a   Ferrari, L ^a   Schieppati, G ^a   Buzzoni, R ^a   Jirillo, A ^a   Amichetti, M ^a   D'Aprile, M ^a   Comella, G ^a   Bichisao, E ^a   Bolelli, G F ^b   Attili, A ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Advanced disease; Aromatase inhibitors; Breast cancer; Formestane

Indexed keywords

ESTRADIOL; ESTRONE; FORMESTANE; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; POSTMENOPAUSE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 8544260297     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008270131789     Document Type: Article

References (21)

1. Johnston SRD, Haynes BP, Smith IE et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 1993; 342: 1521-2.
2. Plowman PN. Tamoxifen as adjuvant therapy in breast cancer. Current status. Drugs 1993; 46: 819-33.
3. Noberasco C, Bajetta E, Zilembo N et al. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Oncology 1995; 5: 454-7.
4. Coombes RC, Hughes SWM, Dowsett M. 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 1992; 28: 1941-5.
5. Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res 1986; 46: 4823-6.
6. Höffken K, Jonat W, Possinger K et al. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: A phase II study. J Clin Oncol 1990; 8: 875-80.
7. Stein RC, Dowsett M, Hedley A et al. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol 1990; 26: 75-8.
8. Bajetta E, Zilembo N, Buzzoni R et al. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. Br J Cancer 1994; 70: 145-50.
9. Dowsett M, Cunningham DC, Stein RC et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306-12.
10. Peréz-Carríon R, Alberola Candel V, Calabresi F et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 1994; 5 (Suppl 7): S19-24.
11. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publication 1979; No. 48.
12. Paradisi R, Lodi S, Bolelli GF et al. Radioimmunoassay of three estrogens and three androgens in the same plasma sample after extraction and chromatographic separation. Acta Endocrinol 1980; 94: 229-39.
13. Ciotti PM, Franceschetti F, Bulletti C et al. Rapid and specific RIA of plasma estrone sulphate with selective solid phase extraction. J Steroid Biochem 1989; 32 (3): 473-4.
14. Hayward JL, Carbone PP, Heuson JC et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
15. Geisler J, Johannessen DC, Anker G et al. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. Eur J Cancer 1996; 32: 789-92.
16. Jones AL, Mac Neil F, Jacobs S et al. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28: 1712-6.
17. Zilembo N, Noberasco C, Bajetta E et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995; 72: 1007-12.
18. Santner SJ, Feil PD, Santen RJ. In situ estrogen production via the estrone sulphatase pathway in breast tumours: Relative importance versus the aromatase pathway. Endocrinol Metab 1984; 59: 29-33.
19. Mac Neil FA, Jacobs S, Lonning PE et al. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression. Br J Cancer 1994; 69: 1171-5.
20. Miller WR, Hawkins RA, Mullen P et al. Aromatase inhibition: Determinants of response and resistance. Endocrine Related Cancer 1995; 2(1): 73-85.
21. Dowsett M, Coombes RC. Second generation aromatase inhibitor - 4-hydroxyandrostenedione. Breast Cancer Res Treat 1994; 30: 81-7.